>>Signaling Pathways>> Microbiology & Virology>> HSV>>Ganciclovir

Ganciclovir (Synonyms: BW 759, 2'Nor2'deoxyguanosine)

Catalog No.GC11331

뉴클레오시드 유사체인 간시클로비르(BW 759)는 CMV에 대한 활성을 갖는 경구 활성 항바이러스제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Ganciclovir Chemical Structure

Cas No.: 82410-32-0

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$45.00
재고 있음
50mg
US$34.00
재고 있음
250mg
US$135.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Ganciclovir (DHPG) is a potent antiviral drug used to treatment of cytomegalovirus (CMV) infections [1].

Ganciclovir (DHPG) is a nucleoside analogue and has shown the activity against viral thymidine kinase (tk) in the Herpesviridae family, including human cytomegalovirus and herpes simplex virus types I and II as well as Epstein-Barr virus. In addition, Ganciclovir has been reported to inhibit the proliferation of uninfected cells, most significantly of bone marrow cells, because of the function of inhibiting viral replication. Apart from these, Ganciclovir has been revealed to reduce the activation of microglial in wild-type C57BL/6 mice and inhibit proliferation of microglial in wild-type FvB mice [1].

References:
[1] Ding Z1, Mathur V, Ho PP, James ML, Lucin KM, Hoehne A, Alabsi H, Gambhir SS, Steinman L, Luo J, Wyss-Coray T. Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation. J Exp Med. 2014 Feb 10; 211(2):189-98.

리뷰

Review for Ganciclovir

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ganciclovir

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.